Corey A. Siegel, MD, MS; Gil Y. Melmed, MD
Drs Corey Siegel, Gil Melmed, and Adam Cheifetz took to the Open Air Studio at the AIBD annual meeting to discuss an important recent change in FDA labeling for upadacitinib and the positioning of JAK inhibitors in the management of IBD.
Drs Corey Siegel, Gil Melmed, and Adam Cheifetz took to the Open Air Studio at the AIBD annual meeting to discuss an important recent change in FDA labeling for upadacitinib and the positioning of JAK inhibitors in the management of IBD.
Drs Corey Siegel, Gil Melmed,...